- Time:
Reliability is paramount when developing targeted cell and gene therapies (CGTs). The current need to control end-product costs will continue in the future as advanced therapies mature and continue to become more widely used. The challenges and costs associated with developing and securing approval for a therapy can reach hundreds of thousands of dollars per dose. Making improvements to the CGT manufacturing process by adopting single-use technologies such as sterile connectors for small-batch processes can help bio-manufacturers save time and money.
In this GEN webinar, Troy Ostreng will discuss CPC’s suite of connector solutions for addressing sterility, chemical compatibility, and ultra-low temperature challenges in the CGT development process, and how they ensure long-term success. Key learnings from the webinar include:
- How to improve operations to make more reliable, faster, and easier sterile connections.
- A complete and validated method for sterile fluid transfer without Bio Safety Cabinets or capital equipment expenditures.
- How aseptic connector solutions support scale-up and scale-out while addressing processing concerns.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.
Senior Product Manager
Colder Products Company
Webinar produced with support from:
